Navigating the Latest Options for the Treatment of CKD in T2D

Download All
In this series of microlearning modules, expert faculty provide insight on new evidence and treatment for chronic kidney disease in type 2 diabetes to improve kidney and cardiovascular outcomes.
Vivian A. Fonseca, MD, FRCP
Program Director
Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP

Nonsteroidal MRA in T2D-associated CKD

In this microlearning module, an expert faculty provides an overview of the cardiorenal benefits of finerenone in patients with type 2 diabetes and chronic kidney disease.

Vivian A. Fonseca, MD, FRCP
Program Director Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Released: August 4, 2022 Expired: No longer available for credit

A leading expert provides an overview of the cardiorenal benefits of finerenone in patients with type 2 diabetes and chronic kidney disease.

Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP Released: July 7, 2022

Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP, summarizes key findings that underpin the use of finerenone in patients with diabetic kidney disease.

Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP Released: August 4, 2022
Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by independent educational grants from
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company
Bayer HealthCare Pharmaceuticals Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings